HBIO Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas

03
Preço $8.34
Capitalização de Mercado (MRQ) $38M
P/E (TTM) -5.6
EPS (TTM) $-1.50
Receita (TTM) $88M
ROE (TTM) -89.9%
Dívida/Capital (MRQ) 4.9
Intervalo 52 Semanas $0–$8

HBIO Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização

04
intervalo
barras

A granularidade da barra se adapta ao período selecionado — passe o mouse sobre o gráfico para ver a abertura/máxima/mínima/fechamento de uma barra.

Divisões de Ações 2
Data ex Desdobramento Tipo
16 de Março de 2026 1-for-10 Reverso
4 de Novembro de 2013 1319-for-1000 Para frente

Sobre Harvard Bioscience, Inc. - Common Stock Visão geral da empresa da Wikipedia

05 · wikidata

Harvard Bioscience is a global developer, manufacturer and marketer of life sciences equipment to support research and drug discovery. It is traded on NASDAQ under the stock symbol HBIO.

Headquartered in Holliston, Massachusetts, United States, the company's brands include: Biochrom, BTX, CMA, Data Sciences International (DSI), Harvard Apparatus, HEKA, Hugo Sachs Elektronik, KD Scientific, Multi Channel Systems (MCS), Panlab, and Warner Instruments. The company has approximately 355 employees, with 216 of those in the USA, and its principal manufacturing facilities are in New Brighton, Minnesota, Holliston, Massachusetts, Reutlingen, Germany, Barcelona, Spain, and March, Germany.

History

Harvard Bioscience was founded in 1901 by Dr. William T. Porter of Harvard Medical School. He began manufacturing his own physiology teaching equipment in the basement of the Harvard Medical School. Dr. Porter went on to found the American Journal of Physiology and became one of the leading physiologists of his day.

The company invented the mechanical syringe pump in the 1950s and a computer-controlled dosing pump in the 1980s.

In the early 1980s, the company started using the name Harvard Bioscience; the name was not officially changed to Harvard Bioscience, Inc. until 2000. The company completed their initial public offering on December 7, 2000. The names Harvard Apparatus and Harvard Bioscience are used pursuant to a license agreement between Harvard University and Harvard Bioscience, Inc.

From 1996 to 2005 the company completed 17 business acquisitions, including the BTX division acquisition in 2003.

In 2007 the company sold most of its Capital Equipment Business, including its Genomic Solutions division and its Belgian subsidiary, Maia Scientific.

The company spun off Harvard Apparatus Regenerative Technology, Inc. (HART) in 2013 and Jeff Duchemin became CEO in August 2013.

In 2014 the company acquired Multi Channel Systems MCS GmbH (MCS) and Triangle BioSystems, Inc. (TBSI).

In 2015 the company acquired HEKA Electronik of Germany.

In 2016 the company divested AHN Biotechnologie GmbH, which it acquired in 2012.

In 2018 Harvard Bioscience acquired St. Paul, Minnesota-based Data Sciences International for $71 million and sold its Denville Scientific subsidiary to Thomas Scientific for $20 million.

James Green was named President and CEO in July 2019 and the company's performance declined during the latter half of his six-year tenure. In 2019, the company's gross revenue was $116 million, down from $120.7 million in 2018. The company ended the year with $55 million in loans, down from $62.4 million in loans at the end of 2018. Loans were through Cerberus Capital and were subsequently refinanced in 2020 with a syndicate led by Citizens Financial Group. In September 2019 the company announced a restructuring program, including closing their Connecticut operation, downsizing in the United Kingdom, and a reduction in force of over 10% of headcount. Several additional restructurings were implemented from 2020 to 2024.

For approximately nine months in 2019-2020 the company had an activist investor in its stock, Engine Capital.

In 2020, during the COVID-19 pandemic, Harvard Bioscience received $6.1 million in federally backed small business loans from PNC Bank as part of the Paycheck Protection Program. The company promptly repaid this loan after receiving scrutiny related to it.

In the of summer of 2025 the board of directors of Harvard Bioscience was reconstituted and a new CEO was appointed and in December 2025 the company successfully refinanced its debt, obtaining a $40 million credit facility with BroadOak Capital.

Products

Harvard Bioscience offers a wide array of products for life science research. Their product portfolio is broken into five market segments: Fluidics, Laboratory Equipment & Supplies, Molecular Analysis, Cell Analysis, and Physiology.

Finance

The revenue of the company grew from $11.5 million in 1997 to $108.2 million in 2010, a CAGR of 19%. The revenue of the company for fy 2013 reached 105.57 million with the profit margin of 0.12% and operation margin of -1.01%.

In the 25 years since Harvard Bioscience went public in 2000, there have been several intervals in which the company's value was grossly misunderstood by the market and its stock significantly undervalued, including, most recently, in 2019 and 2026.

Fonte: Wikipedia (Inglês), CC BY-SA 4.0 · Ver na Wikipedia ↗

Wikidata ↗

setorHealthcare indústriaLife Sciences Tools & Services funcionários316 paísUS

Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS

06
Receita$87M
2016-12-31 → 2025-12-31
EPS$-1.28
2016-12-31 → 2025-12-31
Fluxo de caixa livre$5M
2018-12-31 → 2025-12-31
Margem líquida-11.9%
2016-12-31 → 2025-12-31
Avaliação e Proporções 07–12

Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?

Métrica Tendência de 5 anos HBIO média 5A Mediana de Pares Veredito
P/E (TTM) -5.6média 5A ≈-21.7 ≈-21.7 · ·
P/S (TTM) 0.4média 5A ≈1.4 ≈1.4 · ·
P/B (MRQ) 5.1média 5A ≈2.4 ≈2.4 · ·
EV / EBITDA -1.3média 5A ≈51.1 ≈51.1 · ·
Preço / FCF (TTM) -33.9média 5A ≈802.1 ≈802.1 · ·
Preço / Fluxo de Caixa (TTM) 58.3média 5A ≈83.3 ≈83.3 · ·
EV / Revenue (EV / Receita) 0.7média 5A ≈1.7 ≈1.7 · ·
EV / FCF 11.8média 5A ≈900.4 ≈900.4 · ·
Preço / Valor Patrimonial Tangível (MRQ) 31.7 · · ·

A mediana dos pares é calculada em uma base padronizada por métrica e pode não corresponder sempre à base TTM/MRQ mostrada para esta ação.

valor · ≈ média 5A · mediana do setor · veredicto relativo à mediana

Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados

14
Surpresa Média -18.3%
Próximo relatório Nov 04, 2026
PeríodoRelatórioEPS ActualEPS est.Surpresa
30 de Junho de 2026 Ago 11, 2026 $-0.14 $-0.21 34.6%
31 de Março de 2026 Mai 12, 2026 $-0.77 $-0.63 -21.8%
31 de Dezembro de 2025 $0.00 $0.36 -100.0%
30 de Setembro de 2025 $0.00 $0.05 -100.0%
30 de Junho de 2025 $-0.10 $-0.10 2.0%
31 de Março de 2025 $-0.10 $-0.41 75.5%

Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa

15
Demonstração de Resultados 17
Métrica Tendência 202520242023202220212020201920182017201620152014
Revenue $87M$94M$112M$113M$119M$102M$116M$121M$77M$105M$109M$109M
Cost of Revenue $37M$39M$46M$53M$51M$44M$52M$58M$38M$56M$60M$59M
Gross Profit $50M$55M$66M$61M$68M$58M$64M$63M$39M$48M$49M$49M
R&D Expense $9M$10M$12M$12M$11M$9M$11M$11M$6M$5M$6M$5M
SG&A Expense $18M$21M$23M$24M$24M$24M$23M$21M$18M$21M$20M$17M
Operating Expenses $98M$61M$64M$68M$66M$58M$64M$62M$40M$51M$50M$43M
Operating Income $-49M$-6M$2M$-7M$2M$221.0K$377.0K$984.0K$-635.0K$-3M$-2M$7M
Interest Expense ·······$5M$713.0K$639.0K$846.0K$990.0K
Other Non-op $-3M$-325.0K$-227.0K$302.0K$-666.0K$-806.0K$-469.0K$-4M$-739.0K$-179.0K$-1M$-1M
Pretax Income $-57M$-12M$-3M$-9M$-140.0K$-7M$-6M$-8M$-3M$-3M$-4M$4M
Income Tax $-686.0K$740.0K$859.0K$337.0K$148.0K$518.0K$-815.0K$-4M$-605.0K$1M$15M$2M
Net Income $-57M$-12M$-3M$-10M$-288.0K$-8M$-5M$-3M$-865.0K$-4M$-19M$2M
EPS (Basic) $-1.28$-0.28$-0.08$-0.23$-0.01·$-0.12$-0.08$-0.02$-0.13$-0.57$0.07
EPS (Diluted) $-1.28$-0.28$-0.08$-0.23··$-0.12$-0.08$-0.02$-0.13$-0.57$0.07
Shares (Basic) 44,391,00043,538,00042,420,00041,413,00040,343,00038,640,00037,813,58036,453,12634,753,32534,211,52133,592,77532,170,683
Shares (Diluted) 44,391,00043,538,00042,420,00041,413,00040,343,00038,640,00037,813,58036,453,12634,753,32534,211,52133,592,77533,236,569
EBITDA $-49M$-6M$2M$-7M$2M$221.0K$377.0K$984.0K$-101.0K$-3M$-2M·
Balanço Patrimonial 28
Métrica Tendência 202520242023202220212020201920182017201620152014
Cash & Equivalents $9M$4M$4M$5M$8M$8M$8M$8M$6M$6M$7M$14M
Receivables $16M$15M$16M$17M$22M$18M$21M$21M$13M$16M$18M$16M
Inventory $21M$23M$25M$26M$28M$22M$22M$25M$17M$20M$22M$21M
Other Current Assets $3M$3M$4M$3M$4M$3M$2M$3M$4M$4M$4M$5M
Current Assets $48M$45M$49M$51M$62M$52M$54M$58M$48M$45M$51M$57M
PP&E (Net) $5M$5M$4M$3M$3M$4M$5M$6M$4M$4M$6M$5M
PP&E (Gross) $23M$21M$18M$18M$18M$21M$20M$23M$19M$19M$22M$20M
Accum. Depreciation $18M$16M$14M$15M$14M$17M$15M$17M$16M$15M$16M$15M
Goodwill $10M$56M$57M$56M$58M$59M$57M$57M$36M$38M$40M$40M
Intangibles $8M$11M$16M$21M$27M$33M$38M$46M$10M$17M$21M$21M
Other Non-current Assets $3M$3M$6M$8M$5M$1M$2M$2M$324.0K$128.0K$152.0K$380.0K
Total Assets $80M$127M$137M$145M$162M$156M$165M$169M$109M$108M$120M$136M
Accounts Payable $4M$5M$6M$6M$5M$6M$5M$7M$4M$6M$9M$6M
Accrued Liabilities ······$6M$7M$4M$5M$4M$4M
Current Liabilities $22M$55M$27M$23M$25M$21M$25M$25M$14M$15M$19M$18M
Capital Leases $7M$6M$5M$5M$6M$7M$8M·····
Deferred Tax $317.0K$710.0K$776.0K$590.0K$2M$2M$2M$2M$3M$6M$4M$1M
Other Non-current Liabilities $1M$1M$1M$1M$486.0K$3M$749.0K$3M····
Total Liabilities $66M$63M$64M$73M$79M$80M$83M$86M$28M$36M$42M$40M
Long-term Debt $36M$37M$37M$47M$48M$48M$54M$61M$12M$14M$19M$21M
Total Debt $36M$37M$37M$47M$49M$48M$50M$59M$9M$11M$16M·
Common Stock $447.0K$441.0K$434.0K$454.0K$452.0K$444.0K$438.0K$436.0K$419.0K$418.0K$416.0K$397.0K
Retained Earnings $-215M$-158M$-146M$-142M$-133M$-132M$-125M$-120M$-117M$-116M$-112M$-93M
Treasury Stock ····$0$11M······
AOCI $-12M$-16M$-14M$-15M$-10M$-13M$-13M$-14M$-11M$-17M$-12M$-8M
Stockholders' Equity $14M$63M$73M$72M$83M$77M$82M$83M$81M$72M$78M$95M
Liabilities + Equity $80M$127M$137M$145M$162M$156M$165M$169M$109M$108M$120M$136M
Shares Outstanding 4,471,98944,074,47543,394,50942,081,70741,142,87639,407,08038,188,20837,378,80235,018,47835,018,47833,979,26532,563,256
Fluxo de Caixa 16
Métrica Tendência 202520242023202220212020201920182017201620152014
Stock-based Comp $2M$4M$5M$4M$4M$4M$3M$3M$4M$3M$3M$2M
Deferred Tax $-553.0K$310.0K$228.0K$-498.0K$-371.0K$-143.0K$-398.0K$-4M$-2M$-279.0K$15M$1M
Amort. of Intangibles $4M$5M$6M$6M$6M$6M$6M$5M$2M$3M$3M$3M
Restructuring $200.0K$800.0K$391.0K$2M$1M$2M$1M·$0$-4.0K$788.0K$1M
Operating Cash Flow $7M$1M$14M$1M$1M$9M$8M$3M$1M$5M$705.0K$4M
CapEx $1M$3M$2M$2M$1M$1M$1M$986.0K$890.0K···
Investing Cash Flow $-2M$-1M$-2M$-2M$-1M$-1M$-229.0K$-54M$-917.0K$-62.0K$-8M$-14M
Debt Issued $40M$0··········
Net Debt Issued $15M$-6M$-4M$-3M$-4M$-67M$-12M$-20M$-5M$-9M$-8M·
Stock Issued ·······$5M$160.0K$182.0K$2M$2M
Net Stock Activity ·······$5M$160.0K$182.0K$2M·
Financing Cash Flow $-1M$-131.0K$-12M$-3M$-252.0K$-8M$-8M$53M$-2M$-5M$-540.0K$-1M
Net Change in Cash $5M$-175.0K$-225.0K$-3M$-496.0K$-18.0K$162.0K$2M$137.0K$-1M$-7M$-12M
Taxes Paid $-98.0K$-159.0K$207.0K$534.0K$577.0K$416.0K$374.0K$98.0K$13.0K···
Free Cash Flow $5M$-1M$12M$-438.0K$67.0K$8M$7M$2M····
Levered FCF ·······$-995.1K····
Lucratividade 8
Métrica Tendência 202520242023202220212020201920182017201620152014
Gross Margin 57.7%58.2%58.9%53.7%56.9%56.9%55.4%52.3%46.7%46.3%44.8%·
Operating Margin -56.1%-6.6%1.7%-6.1%1.7%0.22%0.32%0.81%-0.10%-2.9%-1.6%·
Net Margin -65.5%-13.2%-3.0%-8.4%-0.24%-7.6%-4.0%-2.4%-0.85%-4.1%-17.5%·
Pretax Margin -66.3%-12.4%-2.3%-8.1%-0.12%-7.1%-4.7%-6.6%-2.1%-2.9%-3.3%·
EBITDA Margin -56.1%-6.6%1.7%-6.1%1.7%0.22%0.32%0.81%-0.10%-2.9%-1.6%·
ROA -54.9%-9.4%-2.4%-6.2%-0.18%-4.9%-2.8%-2.1%-0.80%-3.8%-14.9%·
ROE -384.8%-19.3%-4.6%-13.2%-0.36%-10.2%-5.9%-3.6%-1.1%-5.8%-22.0%·
ROIC -96.8%-6.6%2.3%-6.0%3.2%0.19%0.24%0.37%-0.05%-5.0%-9.6%·
Liquidez e Solvência 5
Métrica Tendência 202520242023202220212020201920182017201620152014
Current Ratio 2.20.81.82.22.42.52.12.73.43.12.6·
Quick Ratio 1.10.30.80.91.21.21.11.41.61.51.3·
Debt / Equity 2.60.60.50.70.60.60.60.70.10.20.2·
LT Debt / Equity 2.60.00.40.60.50.60.60.70.10.20.2·
Interest Coverage ·······0.2-0.1-4.7-2.0·
Eficiência 3
Métrica Tendência 202520242023202220212020201920182017201620152014
Asset Turnover 0.80.70.80.70.70.60.70.90.90.90.8·
Inventory Turnover 1.71.61.81.92.12.02.22.72.62.72.8·
Receivables Turnover 5.66.16.85.96.05.35.56.96.46.36.5·
Por Ação 5
Métrica Tendência 202520242023202220212020201920182017201620152014
Book Value / Share $0.31$1.44$1.68$1.72$2.03$1.95$2.14$2.21$2.31$2.10$2.28·
Revenue / Share $1.95$2.16$2.65$2.74$2.95$2.64$3.07$3.31$2.93$3.06$3.23·
Cash Flow / Share $0.15$0.03$0.33$0.03$0.03$0.24$0.21$0.08$0.03$0.16$0.02·
Cash / Share $0.19$0.09$0.10$0.11$0.19$0.21$0.22$0.22$0.16$0.16$0.20·
EPS (TTM) $-1.28$-0.28$-0.08$-0.23·$-0.21$-0.12$-0.08$-0.02$-0.13$-0.57$0.07
Taxas de Crescimento 3
Métrica Tendência 202520242023202220212020201920182017201620152014
Revenue YoY -8.1%-16.1%-0.96%-4.7%16.5%·······
Revenue CAGR 3Y -8.6%-7.5%3.2%·········
Revenue CAGR 5Y -3.2%···········
Avaliação (TTM) 13
Métrica Tendência 202520242023202220212020201920182017201620152014
Revenue TTM $87M$94M$112M$113M$119M$102M$116M$121M$77M$105M$109M$109M
Net Income TTM $-57M$-12M$-3M$-10M$-288.0K$-8M$-5M$-3M$-865.0K$-4M$-19M$2M
Market Cap $30M$93M$232M$117M$290M$169M$116M$119M$116M$105M$118M·
Enterprise Value $57M$126M$265M$159M$331M$209M$158M$169M$119M$111M$128M·
P/E -0.5-7.5-66.9-12.0·-20.4-25.4-39.8-165.0-23.5-6.181.0
P/S 0.31.02.11.02.41.71.01.01.51.01.1·
P/B 2.21.53.21.63.52.21.41.41.41.51.5·
P / Cash Flow 4.564.616.5101.2229.818.114.541.2109.319.5167.2·
P / FCF 5.5-77.219.0-266.14329.220.717.162.6····
EV / EBITDA -1.2-20.3139.8-23.0160.1945.8419.8172.2-1176.3-37.0-74.5·
EV / FCF 10.5-104.821.6-363.44938.025.623.289.3····
EV / Revenue 0.71.32.41.42.82.01.41.41.51.11.2·
Earnings Yield -191.0%-13.3%-1.5%-8.3%·-4.9%-3.9%-2.5%-0.61%-4.3%-16.4%1.2%

Período mais recente à esquerda · valores nulos mostrados como ·

Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos

16
Métrica 2025-12-312024-12-312023-12-312022-12-312021-12-31
Receita $87M $94M $112M $113M $119M
Margem Bruta % 57.7% 58.2% 58.9% 53.7% 56.9%
Margem Operacional % -56.1% -6.6% 1.7% -6.1% 1.7%
Lucro líquido $-57M $-12M $-3M $-10M $-288.0K
EPS Diluído $-1.28 $-0.28 $-0.08 $-0.23 ·

Investidores institucionais (13F) 8 declarantes · $5.7M total · Em 30 de Junho de 2026

17

Instituições que relatam a posse desta ação em seu Formulário 13F trimestral da SEC. Apenas posições compradas; um único declarante pode aparecer duas vezes para opções separadas. Grandes posições de compra/venda compensatórias geralmente refletem market-making ou inventário protegido, não convicção direcional.

Detentores 8
Valor detido $5.7M
Novas posições 0
Posições encerradas 0
Atividade institucional — Q2 2026 vs trimestre anterior
Novas posições Posições encerradas Aumentou Diminuído Variação líquida de ações
0 (0 vs trimestre anterior) 0 (-57 vs trimestre anterior) 2 (+2 vs trimestre anterior) 0 (-3 vs trimestre anterior) +90K

Comparado a Q1 2026. Os registros do Formulário 13F da SEC devem ser feitos em até 45 dias após o final do trimestre, mais um pequeno período de tolerância para registrantes atrasados — trimestres ainda dentro desse período são ignorados em favor do par mais recente totalmente reportado.

Instituição Valor Ações % de 13F rastreado Tipo
AMH Equity Ltd $1.774.844 4.047.535 31,32% Ações
VANGUARD GROUP INC $1.286.671 1.923.275 22,71% Ações
Meros Investment Management, LP $1.125.401 182.992 19,86% Ações
NANO CAP NEW MILLENNIUM GROWTH FUND L P $879.954 143.082 15,53% Ações
TWO SIGMA ADVISERS, LP $587.578 878.556 10,37% Ações
Point72 Asia (Singapore) Pte. Ltd. $6.445 14.697 0,11% Ações
WOLVERINE TRADING, LLC $5.102 11.600 0,09% Opção de compra
Financial Connections Group, Inc. $0 30 0,00% Ações

Ativistas e proprietários de 5%+ 5 participações

18

Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.

Declarante Declarado Participação Status Propósito Declaração
BroadOak Income Fund, L.P., BroadOak Fund VI, L.P., BroadOak Capital Partners, LLC, William Snider 23 de Março de 2026 15,97% Declaração inicial · SEC
ENGINE CAPITAL, L.P., ENGINE JET CAPITAL, L.P., ENGINE CAPITAL MANAGEMENT, LP, ENGINE CAPITAL MANAGEMENT GP, LLC, ENGINE INVESTMENTS, LLC, ARNAUD AJDLER ×5 declarações 22 de Junho de 2020 · Declaração inicial · SEC
HSO Limited Partnership Skystone Advisors LLC Kerry Nelson ×2 declarações 20 de Maio de 2008 · Declaração inicial · SEC
14 de Dezembro de 2007 · Declaração inicial · SEC
Pessoa de relato não divulgada 29 de Julho de 2002 · Declaração inicial M&A / venda SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Executivos da empresa 34 insiders · 14 diretores · 18 conselheiros

19
Investidor com informação privilegiada Função Última atividade Ações detidas Compras 12m Vendas 12m Líquido 12m
John D Duke Chief Executive Officer 20 de Março de 2026 A 180.000 1 0 $25.050
Jeffrey Duchemin Chief Executive Officer 7 de Julho de 2019 D 464.528 0 0 $0
Mark T Frost Chief Financial Officer 20 de Março de 2026 A 47.500 1 0 $25.000
Jennifer Cote Chief Financial Officer 19 de Março de 2025 F 159.019 0 0 $0
Michael A. Rossi Chief Financial Officer 29 de Dezembro de 2022 F 260.540 0 0 $0
Kamalam Unninayar Chief Financial Officer 7 de Março de 2019 A 73.858 0 0 $0
Bryce Anthony Chicoyne Chief Financial Officer 1 de Maio de 2007 A · 0 0 $0
Mark A Norige President, Harvard Apparatus 1 de Maio de 2007 A · 0 0 $0
David L Strack President of Subsidiary 25 de Maio de 2005 A · 0 0 $0
Kenneth Fletcher Olson Chief Operating Officer 29 de Dezembro de 2021 F 155.595 0 0 $0
Yash Singh Executive Vice President 31 de Outubro de 2019 A 39.286 0 0 $0
Yong Sun VP - Commercial Operations 1 de Janeiro de 2019 F 242.805 0 0 $0
Yoav Sibony VP - Global Sales 3 de Agosto de 2015 A 21.582 0 0 $0
Paul Bailey VP, Finance & Admin. 25 de Maio de 2005 A · 0 0 $0
Seth Benjamin Benson Conselheiro 9 de Junho de 2026 A 27.556 0 0 $0
Katherine A. Eade Conselheiro 9 de Junho de 2026 A 58.669 0 0 $0
Robert E. Gagnon Conselheiro 9 de Junho de 2026 A 27.556 0 0 $0
William Snider Conselheiro 9 de Junho de 2026 A 48.556 2 0 $103.604
Stephen J Denelsky Conselheiro 9 de Junho de 2026 A 37.556 1 0 $48.700
James W Green Conselheiro 15 de Agosto de 2025 D 2.452.566 0 0 $0
Thomas W Loewald Conselheiro 21 de Maio de 2024 A 295.311 0 0 $0
Bertrand Loy Conselheiro 21 de Maio de 2024 A 56.575 0 0 $0
Alan I Edrick Conselheiro 21 de Maio de 2024 A 273.911 0 0 $0
John F Kennedy Conselheiro 23 de Março de 2021 G 323.344 0 0 $0
Susan M. Steele Conselheiro 4 de Janeiro de 2021 A 49.400 0 0 $0
George Uveges Conselheiro 12 de Março de 2018 M 142.685 0 0 $0
Earl R Lewis Conselheiro 2 de Janeiro de 2018 A 477.050 0 0 $0
David Green Conselheiro 7 de Fevereiro de 2017 S 925.571 0 0 $0
Neal J Harte Conselheiro 25 de Maio de 2016 M 106.399 0 0 $0
Robert A Dishman Conselheiro 28 de Abril de 2015 A 51.055 0 0 $0
Chane Graziano Detentor de 10% 7 de Novembro de 2013 G 3.005.150 0 0 $0
HSO LIMITED PARTNERSHIP Detentor de 10% 16 de Maio de 2008 S 2.757.257 0 0 $0
Thomas Mcnaughton · 1 de Novembro de 2013 J 171.613 0 0 $0
Susan M Luscinski · 1 de Novembro de 2013 J 469.720 0 0 $0

Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto

Participação em ETFs Detido por 2 ETFs

20

O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.

Fundo Peso Unidades Em Fonte
VXF · VANGUARD INDEX FUNDS 0,00% 42.043 SH 19 de Agosto de 2026 Diário
VTI · VANGUARD INDEX FUNDS 0,00% 123.470 SH 19 de Agosto de 2026 Diário

HBIO Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta

21
classificação · 8 analistas COMPRA
Alvo mediano $7.50 -10,1%
2 25,0% Compra forte
4 50,0% Compra
2 25,0% Manter
0 0,0% Venda
0 0,0% Venda forte

Preço-alvo de 12 meses

1 analistas · 2026-10-04

Alvo médio $7.50 -10,1%

Mín$7.50 Média$7.50 Máx$7.50

Comparação de pares (subindústria GICS) Métricas chave vs pares do setor

22

Base do ano fiscal, preços no fechamento do último ano fiscal de cada empresa.

Ticker Capitalização de Mercado P/E Receita YoY Margem Líquida ROE Margem Bruta
HBIO $30M -0.5 -8.1% -65.5% -384.8% 57.7%
HYFT · · · -89.7% -78.9% 58.8%
CIRC · · · · · ·
RPID · -2.8 19.7% -140.3% -107.4% ·
BNGO $16M -0.3 -7.4% -92.6% -58.8% ·
TMO $257.86B 32.7 3.9% 15.0% 13.0% ·

Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos

26

Escolha as métricas que importam para si — clique no + ao lado de qualquer linha em Fundamentos Completos acima.

Sua seleção é salva e acompanha você em todos os tickers.

Fonte: SEC 10-Q arquivado Ago 11, 2026